Dynavax Technologies (NASDAQ:DVAX) Stock Price Down 3.4%

Shares of Dynavax Technologies Co. (NASDAQ:DVAX) were down 3.4% during mid-day trading on Friday . The stock traded as low as $11.44 and last traded at $11.45. Approximately 249,494 shares changed hands during trading, a decline of 88% from the average daily volume of 2,032,097 shares. The stock had previously closed at $11.85.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on DVAX. StockNews.com raised shares of Dynavax Technologies from a “hold” rating to a “buy” rating in a research note on Monday. William Blair reiterated an “outperform” rating on shares of Dynavax Technologies in a report on Friday, February 23rd. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 price target on shares of Dynavax Technologies in a research note on Thursday, May 9th. Finally, The Goldman Sachs Group started coverage on Dynavax Technologies in a report on Thursday, February 1st. They issued a “neutral” rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.33.

Dynavax Technologies Trading Down 4.3 %

The company’s fifty day moving average is $11.75 and its two-hundred day moving average is $12.81. The company has a quick ratio of 14.10, a current ratio of 15.20 and a debt-to-equity ratio of 0.36. The stock has a market cap of $1.48 billion, a price-to-earnings ratio of 197.50 and a beta of 1.30.

Insiders Place Their Bets

In other Dynavax Technologies news, CAO Justin Burgess sold 20,526 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $12.78, for a total value of $262,322.28. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. 2.98% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently modified their holdings of DVAX. Vanguard Group Inc. increased its holdings in shares of Dynavax Technologies by 1.4% in the 1st quarter. Vanguard Group Inc. now owns 9,402,246 shares of the biopharmaceutical company’s stock valued at $116,682,000 after purchasing an additional 126,458 shares in the last quarter. Kynam Capital Management LP raised its position in Dynavax Technologies by 180.0% during the first quarter. Kynam Capital Management LP now owns 4,239,780 shares of the biopharmaceutical company’s stock worth $52,616,000 after acquiring an additional 2,725,397 shares during the last quarter. Dimensional Fund Advisors LP lifted its holdings in shares of Dynavax Technologies by 7.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 4,032,139 shares of the biopharmaceutical company’s stock valued at $56,372,000 after purchasing an additional 293,337 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Dynavax Technologies by 21.8% during the 4th quarter. Goldman Sachs Group Inc. now owns 3,597,139 shares of the biopharmaceutical company’s stock worth $50,288,000 after purchasing an additional 644,428 shares in the last quarter. Finally, Eventide Asset Management LLC raised its position in shares of Dynavax Technologies by 103.0% during the 4th quarter. Eventide Asset Management LLC now owns 2,893,435 shares of the biopharmaceutical company’s stock worth $40,450,000 after purchasing an additional 1,468,435 shares during the last quarter. Institutional investors and hedge funds own 96.96% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe.